After the screening visit, the study team will meet to determine if the patient will continue to remain in the study. If a patient does remain in the study, he/she will be invited to a randomization visit. Patients will be randomized into either the Duloxetine group or the placebo control group. The data and safety monitor will use a randomization software. This program allows the researcher to enter in the number of subject, and condition, and will generate a table of randomly assigned patients to condition. The patients and study personnel will be blinded to the condition. The data safety monitor will randomly assign patients to condition and work with the pharmacy to properly label the study drugs. Only the data monitoring personnel will be un-blinded and will generate the table of random numbers. After randomization, patients will undergo vitals, interviews, testing, and the study drug will be dispensed to them. First dosage will consist of 30 mg of Duloxetine or placebo, and the participant will be asked to take the first dose at this visit.